跳转至内容
Merck

R0900000

Rifamycin B

European Pharmacopoeia (EP) Reference Standard

别名:

Rifamycin impurity A

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C39H49NO14
CAS号:
分子量:
755.80
Beilstein:
604953
分類程式碼代碼:
41116107
NACRES:
NA.24

等級

pharmaceutical primary standard

API 家族

rifamycin, rifampicin

製造商/商標名

EDQM

應用

pharmaceutical (small molecule)

格式

neat

儲存溫度

2-8°C

InChI

1S/C39H49NO14/c1-17-11-10-12-18(2)38(49)40-24-15-26(51-16-27(42)43)28-29(34(24)47)33(46)22(6)36-30(28)37(48)39(8,54-36)52-14-13-25(50-9)19(3)35(53-23(7)41)21(5)32(45)20(4)31(17)44/h10-15,17,19-21,25,31-32,35,44-47H,16H2,1-9H3,(H,40,49)(H,42,43)/b11-10+,14-13+,18-12-/t17-,19+,20+,21+,25-,31-,32+,35+,39-/m0/s1

InChI 密鑰

SQTCRTQCPJICLD-KTQDUKAHSA-N

正在寻找类似产品? 访问 产品对比指南

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

應用

Rifamycin B EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

包裝

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他說明

Sales restrictions may apply.

儲存類別代碼

11 - Combustible Solids

閃點(°F)

Not applicable

閃點(°C)

Not applicable


从最新的版本中选择一种:

分析证书(COA)

Lot/Batch Number

抱歉,我们目前尚未线上提供该产品的COA。

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

A Courtois et al.
Cancer letters, 139(1), 97-104 (1999-07-17)
The multidrug resistance-associated protein (MRP) is a drug efflux membrane pump conferring multidrug resistance on tumor cells. In order to look for compounds that can lead to reversal of such a resistance, the antituberculosis compound rifampicin, belonging to the chemical
Ansgar Stratmann et al.
The Journal of antibiotics, 55(4), 396-406 (2002-06-14)
Proansamycin B, the formerly postulated intermediate of rifamycin B biosynthesis, was isolated from cultures of the Amycolatopsis mediterranei mutant F1/24. The structure was determined using UV, IR, NMR and MS techniques. Biotransformation studies demonstrate that proansamycin B is an intermediate
A Stratmann et al.
Microbiology (Reading, England), 145 ( Pt 12), 3365-3375 (2000-01-08)
Rifamycin B biosynthesis in Amycolatopsis mediterranei N/813 was inactivated by introducing a small deletion in the rifF gene situated directly downstream of the rifamycin polyketide synthase (PKS) gene cluster. The corresponding mutant strain produced a series of linear intermediates of
Feifei Qi et al.
Nature communications, 9(1), 2342-2342 (2018-06-16)
Rifamycin-derived drugs, including rifampin, rifabutin, rifapentine, and rifaximin, have long been used as first-line therapies for the treatment of tuberculosis and other deadly infections. However, the late steps leading to the biosynthesis of the industrially important rifamycin SV and B
Prashant M Bapat et al.
Biotechnology and bioengineering, 93(4), 779-790 (2005-11-23)
Industrial fermentations typically use media that are balanced with multiple substitutable substrates including complex carbon and nitrogen source. Yet, much of the modeling effort to date has mainly focused on defined media. Here, we present a structured model that accounts

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门